Viridian Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $141 | $132 | $70,570 | $75 |
Gross Profit | 20 | -188 | 70,570 | 75 |
EBITDA | -116,169 | -114,087 | -33,929 | -100,108 |
EBIT | -116,290 | -113,747 | -34,039 | -100,221 |
Net Income | -104,901 | -120,355 | -34,599 | -100,735 |
Net Change In Cash | 141 | 132 | 70,570 | 75 |
Free Cash Flow | -119,677 | -23,994 | -84,738 | -75,415 |
Cash | 176,346 | 212,382 | 169,647 | 117,324 |
Basic Shares | 102,211 | 84,803 | 81,784 | 81,593 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $70,849 | $302 | $314 | $1,772 |
Gross Profit | 70,849 | 302 | 314 | 1,772 |
EBITDA | -337,193 | -265,663 | -235,365 | -129,133 |
EBIT | -337,653 | -266,903 | -235,887 | -129,388 |
Net Income | -342,601 | -269,949 | -237,734 | -129,874 |
Net Change In Cash | 70,849 | 302 | 314 | 1,772 |
Cost of Revenue | 113,280 | |||
Free Cash Flow | -276,886 | -232,830 | -185,068 | -94,635 |
Cash | 212,382 | 99,594 | 102,827 | 155,579 |
Basic Shares | 84,803 | 67,886 | 44,755 | 32,087 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.90 |
2025-12-31 | -$1.08 |
2025-09-30 | -$0.34 |
2025-06-30 | -$1 |